Literature DB >> 3498769

Chemotactic effect of human recombinant interleukin 2 on mouse activated large granular lymphocytes.

R J Natuk1, R M Welsh.   

Abstract

Human recombinant interleukin 2 (hrIL-2) was demonstrated in vitro to be chemotactic for mouse large granular lymphocytes (LGL) activated in vivo by virus infection. Peritoneal exudate cells harvested from virus-infected mice were used as a source of LGL. LGL collected from mouse hepatitis virus-infected mice at 3 days postinfection were a source for NK 1.1 positive natural killer (NK)/LGL. LGL collected from mice treated with antiserum to gangliotetraosylceramide and infected with lymphocytic choriomeningitis virus for 7 days were used as a source for Lyt-2 positive cytotoxic T lymphocytes (CTL)/LGL. Both NK/LGL and CTL/LGL responded chemotactically to hrIL-2, purified IFN-beta, and to crude cell-free washout fluids collected from the peritoneal cavity of virus-infected mice. hrIL-2 had chemotactic activity for virus-elicited granular and agranular lymphocytes but did not attract the contaminating macrophages, in contrast to IFN-beta, which displayed chemotactic activity for virus-elicited granular and agranular lymphocytes as well as macrophages. The migration to hrIL-2 was inhibited by a monoclonal antibody (7D4) to the IL-2 receptor, but treatment with 7D4 did not affect migration in response to IFN-beta. Microscopic examination of Wright's-Giemsa-stained migrated NK/LGL and CTL/LGL revealed that the majority of migrated LGL in either LGL population had a blast cell morphology (enlarged cells with rich basophilic cytoplasm). The frequency of cells bearing the LGL morphology within the virus-elicited nonadherent peritoneal exudate cell population was on incubation in vitro, stabilized by either hrIL-2 or IFN-beta. These data suggest that another important immunomodulating function of IL-2 may be to attract activated NK/LGL and CTL/LGL to sites of inflammation.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3498769

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

Review 1.  Immunotherapy for malignant glioma using human recombinant interleukin-2 and activated autologous lymphocytes. A review of pre-clinical and clinical investigations.

Authors:  R E Merchant; M D Ellison; H F Young
Journal:  J Neurooncol       Date:  1990-04       Impact factor: 4.130

2.  Acute and chronic inflammatory responses to local administration of recombinant IL-1 alpha, IL-beta, TNF alpha, IL-2 and Ifn gamma in mice.

Authors:  C J Dunn; M M Hardee; N D Staite
Journal:  Agents Actions       Date:  1989-06

3.  Distinct organ-dependent mechanisms for the control of murine cytomegalovirus infection by natural killer cells.

Authors:  C H Tay; R M Welsh
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

4.  Totally implanted catheters to reduce catheter-related infections in patients receiving interleukin-2: a 2-year experience.

Authors:  B Escudier; J L Lethiec; E Angevin; A Andremont; M F Cosset-Delaigue; S Antoun; B Leclercq; G Nitenberg
Journal:  Support Care Cancer       Date:  1995-09       Impact factor: 3.603

5.  Antiviral effect of lymphokine-activated killer cells: chemotaxis and homing to sites of virus infection.

Authors:  R J Natuk; J F Bukowski; J O Brubaker; R M Welsh
Journal:  J Virol       Date:  1989-11       Impact factor: 5.103

6.  Interleukin 2-induced proliferation of murine natural killer cells in vivo.

Authors:  C A Biron; H A Young; M T Kasaian
Journal:  J Exp Med       Date:  1990-01-01       Impact factor: 14.307

7.  Natural killer (NK) cell response to virus infections in mice with severe combined immunodeficiency. The stimulation of NK cells and the NK cell-dependent control of virus infections occur independently of T and B cell function.

Authors:  R M Welsh; J O Brubaker; M Vargas-Cortes; C L O'Donnell
Journal:  J Exp Med       Date:  1991-05-01       Impact factor: 14.307

8.  Transforming growth factor beta 1 (TGF-beta 1) produced in tumour tissue after chemotherapy acts as a lymphokine-activated killer attractant.

Authors:  Y Kuramitsu; M Nishibe; M Kobayashi; Y Togashi; L Yuan; M Takizawa; F Okada; M Hosokawa
Journal:  Br J Cancer       Date:  1996-07       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.